Download MendeleyStructure-Activity Relationship of Oxacyclo- and Triazolo-Containing Respiratory Syncytial Virus Polymerase Inhibitors.
Tran, M.T., Grosse, S., Carbajo, R.J., Jacoby, E., Yin, Y., Yu, X., Martinez, C., Stoops, B., Cooymans, L., Hu, L., Lutter, F.H., Pieters, S., Tan, E., Alcazar, J., Roymans, D., van Vlijmen, H., Rigaux, P., Sharma, S., Jonckers, T.H.M.(2024) ACS Med Chem Lett 15: 1549-1558
- PubMed: 39291020
- DOI: https://doi.org/10.1021/acsmedchemlett.4c00272
- Primary Citation of Related Structures:
9C7Y - PubMed Abstract:
Despite the availability of medicines preventing respiratory syncytial virus (RSV) infection, post-exposure treatment options are needed for addressing patient's needs. RSV non-nucleoside polymerase inhibitors (NNI) have emerged as a promising asset for which our group previously disclosed JNJ-8003 with potent in vitro antiviral activity and pronounced in vivo efficacy. In this work, a structural-guided design to modify the linker vector of JNJ-8003 resulted in the identification of 2-oxacyclo pyridine-containing derivatives whose various ring closing strategies are described. In addition, bioisosteric replacement of an amide bond with triazole retained potency, and cryo-electron microscopy (cryo-EM) confirmed binding in the capping domain. Subsequent NMR conformational analysis suggested a correlation between the potency and conformations. Our efforts have fulfilled the aim of identifying linker modifications with maintained biological activity while enriching structural diversity and allowing modulations of other parameters.
- Janssen Pharmaceutica NV, 2340 Beerse, Belgium.
Organizational Affiliation:
